Enanta Pharmaceuticals (ENTA) announced that the United States District Court of Massachusetts has issued a ruling on a summary judgment motion filed by Pfizer (PFE) in connection with Enanta’s patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 in the manufacture, use and sale of Pfizer’s COVID-19 antiviral, Paxlovid. The Court issued a summary judgment decision granting Pfizer’s motion that the ‘953 Patent is invalid. In its decision, the Court also denied Enanta’s partial motion for summary judgment of infringement as moot in light of its allowance of summary judgment on invalidity. Enanta plans to appeal the decision to the Court of Appeals for the Federal Circuit.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA:
- Enanta price target lowered to $18 from $27 at H.C. Wainwright
- Enanta price target lowered to $20 from $30 at Evercore ISI
- Enanta Pharmaceuticals Reports Promising Results for Pediatric RSV Drug
- Enanta announces ‘positive’ results from Phase 2 study of zelicapavir
- Enanta Pharmaceuticals’ Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility